GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Medical Solutions Group PLC (FRA:AQA) » Definitions » Debt-to-EBITDA

Advanced Medical Solutions Group (FRA:AQA) Debt-to-EBITDA : 0.31 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Advanced Medical Solutions Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Advanced Medical Solutions Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1.4 Mil. Advanced Medical Solutions Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €9.3 Mil. Advanced Medical Solutions Group's annualized EBITDA for the quarter that ended in Dec. 2023 was €33.7 Mil. Advanced Medical Solutions Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.31.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Advanced Medical Solutions Group's Debt-to-EBITDA or its related term are showing as below:

FRA:AQA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.28   Med: 0.32   Max: 0.64
Current: 0.28

During the past 13 years, the highest Debt-to-EBITDA Ratio of Advanced Medical Solutions Group was 0.64. The lowest was 0.28. And the median was 0.32.

FRA:AQA's Debt-to-EBITDA is ranked better than
79.27% of 439 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs FRA:AQA: 0.28

Advanced Medical Solutions Group Debt-to-EBITDA Historical Data

The historical data trend for Advanced Medical Solutions Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Medical Solutions Group Debt-to-EBITDA Chart

Advanced Medical Solutions Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.34 0.64 0.32 0.28 0.28

Advanced Medical Solutions Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.28 0.27 0.26 0.31

Competitive Comparison of Advanced Medical Solutions Group's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Medical Solutions Group's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Advanced Medical Solutions Group's Debt-to-EBITDA falls into.



Advanced Medical Solutions Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Advanced Medical Solutions Group's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.351 + 9.255) / 37.526
=0.28

Advanced Medical Solutions Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.351 + 9.255) / 33.734
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Advanced Medical Solutions Group  (FRA:AQA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Advanced Medical Solutions Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Advanced Medical Solutions Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Medical Solutions Group (FRA:AQA) Business Description

Traded in Other Exchanges
Address
Premier Park, 33 Road One, Winsford Industrial Estate, Winsford, Cheshire, GBR, CW7 3RT
U.K.-based Advanced Medical Solutions was founded in 1991 to design, develop, and manufacture advanced wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The firm derives approximately 60% of total revenue from branded products, with nonbranded contributing 40%.

Advanced Medical Solutions Group (FRA:AQA) Headlines

No Headlines